Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023. The Board determined that Mr. Shapiro qualifies as an independent director under the listing rules of the Nasdaq Capital Market.
Ben Shapiro is a successful entrepreneur and business professional who co-founded The Daily Wire, a successful, industry leading, international media outlet in June 2015. Since May 2015, he is host of “The Ben Shapiro Show,” a popular podcast, and he is the author of numerous New York Times best-selling books.
Mr. Shapiro earned a B.A. in Political Science from UCLA in 2004, summa cum laude, and a law degree from Harvard Law School in 2007, cum laude.
Mr. Shapiro beneficially owns over four percent of Oramed’s outstanding stock, making him a significant shareholder in the Company.
The combination of Mr. Shapiro’s ownership stake and his real ability to add value to the Board due to his extensive operational and business background and acumen makes him a valuable addition.
“We are excited to welcome Ben onto our Board. Ben’s unique talents and qualifications are expected to bring real value to the current Oramed Board. We are delighted to begin working in earnest with him to build shareholder value,” said Oramed Chief Executive Officer, Nadav Kidron.
Mr. Shapiro said, “I believe Oramed is in a unique position to utilize its current capital effectively in ways that will be beneficial to its shareholders, given its skilled management and cash position. I am happy to join Oramed’s Board in what I am sure will be an exciting future for Oramed and its shareholders.”
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. The Company’s novel Protein Oral Delivery (POD™) technology is designed to protect drug integrity and increase absorption. Oramed has offices in the United States and Israel. For more information, please visit www.oramed.com.
